Jason Hou
Overview
Explore the profile of Jason Hou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cohen-Mekelburg S, Johnson J, Paine E, Prasad M, Dominitz J, Hou J
Dig Dis Sci
. 2024 Jul;
69(9):3180-3187.
PMID: 39068377
Background: The barriers to providing high-quality inflammatory bowel disease (IBD) care go beyond educational needs alone to include access to IBD-related resources such as medications, laboratory testing, and multidisciplinary teams....
2.
Falloon K, Dossaji Z, Mude P, Abushamma S, Ananthakrishnan A, Barnes E, et al.
Inflamm Bowel Dis
. 2024 Jun;
31(3):812-842.
PMID: 38836521
Background: Inflammatory bowel disease (IBD)-associated peripheral spondyloarthritis (pSpA) decreases quality of life and remains poorly understood. Given the prevalence of this condition and its negative impact, it is surprising that...
3.
Noureldin M, Van T, Cohen-Mekelburg S, Scott F, Higgins P, Stidham R, et al.
Am J Gastroenterol
. 2024 May;
119(10):2130-2133.
PMID: 38767951
Introduction: Cannabis may provide inflammatory bowel disease (IBD) patients with an alternative to opioids for pain. Methods: We conducted a difference-in-difference analysis using MarketScan. Changes over time in rates of...
4.
Yang M, Li Q, Baser R, Li X, Hou J, Mao J
Biomed Pharmacother
. 2024 May;
175:116728.
PMID: 38733772
Patients' expectations and beliefs regarding the potential benefits and harms of medical interventions may induce placebo and nocebo effects, and affect the response to pain therapies. In a randomized clinical...
5.
Chang N, Chanfreau-Coffinier C, Bates J, Tuteja S, Anglin T, Moore V, et al.
J Pharm Policy Pract
. 2023 Dec;
16(1):166.
PMID: 38082299
Pharmacogenetic (PGx) testing before initiation of thiopurine treatment and CBC monitoring post-initiation helps avoid adverse events and ensure patient safety. This study aims to evaluate trends in PGx testing and...
6.
Armuzzi A, Cross R, Lichtenstein G, Hou J, Deepak P, Regueiro M, et al.
Clin Gastroenterol Hepatol
. 2023 Dec;
22(5):1067-1076.e3.
PMID: 38040274
Background & Aims: Evaluating cardiovascular safety of sphingosine 1-phosphate (S1P) receptor modulators is warranted due to S1P receptor expression on cardiomyocytes and vascular endothelial cells. This analysis reports the cardiovascular...
7.
Cohen-Mekelburg S, Van T, Wallace B, Berinstein J, Yu X, Lewis J, et al.
Am J Gastroenterol
. 2023 Aug;
118(8):1462-1463.
PMID: 37534810
No abstract available.
8.
Marino D, Singh S, Hou J, Siegel C, Melmed G, Shah S
R I Med J (2013)
. 2022 Oct;
105(9):25-29.
PMID: 36300960
With the advent of biologic agents, the treatment of patients with Inflammatory Bowel Diseases (IBD) has changed from managing symptoms to achieving remission of disease. Disease remission is associated with...
9.
Lu H, Hou J, Takahashi Y, Tamura Y, Kasugai S, Kuroda S, et al.
Medicina (Kaunas)
. 2022 Oct;
58(10).
PMID: 36295663
In the original publication [...].
10.
Cohen-Mekelburg S, Van T, Wallace B, Berinstein J, Yu X, Lewis J, et al.
Am J Gastroenterol
. 2022 Aug;
117(11):1851-1857.
PMID: 35970816
Introduction: Studies suggest that nonsteroidal anti-inflammatory drugs (NSAID) may contribute to inflammatory bowel disease (IBD) exacerbations. We examined whether variation in the likelihood of IBD exacerbations is attributable to NSAID....